Multiple recent guidelines and recommendations, in both the clinical and research realms, call for reporting of genetic information (including incidental information) that is clinically useful to patients and research participants and suggest it is appropriate to withhold information that is inaccurate, not actionable, or could potentially lead to harm. Although based on sound ethical principles, including beneficence and respect for persons, these guidelines hav e largely ignored an important biological phenomenon long-recognized in genetics: pleiotropy , the concept of a single gene or genetic v ariant affecting multiple phenoty pes. V ariants in some genes hav e related pleiotropic effects (eg, BRCA1 and BRCA2 mutations increasing susceptibility for multiple cancer ty pes), and v ariants in other genes affect multiple phenoty pes that are less similar (eg, mutations in PAH leading to pheny lketonuria, eczema, light pigmentation, and mental retardation). Insofar as current recommendations do not account for pleiotropy , such guidelines are incomplete-and in some cases, contradictory . This could pose important practical problems for clinicians and inv estigators who may be try ing to decide which, if any , genetic results to return to patients or to study participants.
Large numbers of potentially reportable genetic v ariants are likely to be generated from wholegenome sequencing and related approaches. Most current guidelines attempt to assign these v ariants to 1 of 3 categories: those that should be returned (results giv en), those that may be returned (results offered), and those that should not be returned (results withheld). V ariants are ty pically assigned to these categories according to their clinical v alidity (ie, the v alidity and strength of the genoty pe-phenoty pe association) and clinical utility (ie, whether information about a specific genoty pe is useful for treatment or prev ention of disease). Other criteria can include personal utility or analy tic v alidity . Howev er, all current guidelines appear to apply these criteria with reference to a single genoty pe-phenoty pe association, without considering such associations in the contex t of additional pleiotropic relationships. In some instances, this can lead to conflicting conclusions regarding whether it is appropriate to return a particular genetic result.
One well-known ex ample inv olv es the APOE gene, for which apply ing current criteria to different phenoty pic associations with the same genetic v ariant (ε4) may lead to recommendations that this information may be returned (due to its implications for cardiov ascular disease risk, a potentially actionable phenoty pe) and, simultaneously , should not be returned (due to its associations with a nonmodifiable risk of dev eloping Alzheimer disease). In the face of such conflicting recommendations, an inv estigator or clinician must decide whether it is more appropriate to not return any information (av oiding potential harm), return only the clinically useful association (promoting potential benefit), or opt instead for full disclosure of all relev ant associations, on the assumption that patients hav e a right to this information and that the benefits outweigh the potential disadv antages of receiv ing unwanted or unhelpful information. Howev er, returning only one of sev eral pleiotropic associations will not alway s be feasible, because a simple web search of the genoty pe by the patient or participant may readily rev eal the other associations. In an era of increasing information av ailability , media attention, personal health information accessibility , and medical self-management, there is potential for inadv ertent psy chosocial or phy sical harm to result from a participant or patient discov ering pleiotropic genetic information. This may particularly be the case when ancillary information inv olv es risks for a disease that is more sev ere, life-threatening, stigmatizing, or less treatable than the initial indication. In addition, such independent discov ery of additional pleiotropic associations may occur long after any initial contact with a clinician, researcher, or genetic counselor. Do clinicians or researchers hav e a responsibility to prov ide this information to patients or research participants?
Although this problem of pleiotropy for the return of APOE results has been prev iously acknowledged, increasing ev idence of the perv asiv eness of pleiotropy suggests that this will not be an isolated ex ample. A recent study found that 233 of the 1 380 genes in the National Human Genome Research Institute's Genome-Wide Association Studies catalog (1 7 %) had pleiotropic effects. Another study found that 1 6 of 42 pharmacogenetic genes (38%) gav e risk information for diseases other than the pharmacogenetic indication. Additionally , sev eral genes appear to be highly pleiotropic: v ariants in the TERT locus, for ex ample, hav e been associated with at least 24 different tumor ty pes. Moreov er, as the identification of pleiotropy requires at least one association to be prev iously reported, both the number of genes that demonstrate pleiotropic effects, as well as the number of pleiotropic associations for a giv en gene, can be ex pected to ex pand as genetic knowledge increases. Indeed, sev eral studies are activ ely searching for new pleiotropic relationships with known genetic v ariants. Additionally , efforts to quantify the degree of pleiotropy in animal models suggest that pleiotropy is common in the genome, and that some genes hav e a large number of pleiotropic effects. Of the 56 ACMG genes, 43 (7 7 %) had multiple associated phenoty pes listed, with an av erage of 3.5 phenoty pes per gene (range, 1 -1 1 ; eFigure in the Supplement). Thus, while reporting v ariants in these genes prov ides information about the 55 actionable phenoty pes described in the recommendations, these v ariants also prov ide information for an additional 1 1 6 phenoty pic relationships (up to 1 0 per gene) that are not otherwise mentioned or acknowledged. Together, this ex ample suggests that ev en stringent attempts to limit disclosure of incidental findings to only a highly scrutinized list are still likely to prov ide additional pleiotropic information that may not meet the same criteria for reporting to patients or research participants.
The broad perv asiv eness of pleiotropy , and ev ident complications it poses for return decisionmaking, demands proactiv e consideration by clinicians, researchers, and policy makers with an interest in ensuring responsible communication of genetic information. Pleiotropy poses important implications for return of result decision making, as well as research ov ersight and health care management. Specifically , more complete classification schemes that consider pleiotropic associations will be needed to determine which results are appropriate to return to patients and research participants, and under what circumstances. The dev elopment of such schemes will likely require further policy discussion about how best to weigh the ev idence of pleiotropic associationsincluding the ty pe and degree of ancillary information implicated-against other criteria such as clinical utility . Ideally , procedures for ev idence rev iew and criteria gov erning return decisions in the presence of pleiotropy would be widely disseminated and discussed. Resources will also need to be dev oted to ex ploring the responsible return of pleiotropic information, including clinician, researcher, patient, and participant understandings of the salience of such information. In addition, informed consent practices may need to be dev eloped that specifically acknowledge pleiotropy and ex plain the likely conv ey ance of additional information of unknown significance with potentially any returned genetic result.
Although pleiotropy has been documented by geneticists for more than 1 00 y ears, its effect on the return of results from genomic analy sis is y et to be recognized. Clinicians and researchers should be aware that additional phenoty pes may be associated with any giv en genetic result returned and that Results provided by:
Advertisement association studies (PheWAS) for ex ploration of nov el genoty pe-phenoty pe relationships and pleiotropy discov ery . 
